Biomea Fusion (BMEA) Stock Forecast, Price Target & Predictions
BMEA Stock Forecast
Biomea Fusion stock forecast is as follows: an average price target of $13.67 (represents a 74.14% upside from BMEA’s last price of $7.85) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
BMEA Price Target
The average price target for Biomea Fusion (BMEA) is $13.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $5.00. This represents a potential 74.14% upside from BMEA's last price of $7.85.
BMEA Analyst Ratings
According to 5 Wall Street analysts, Biomea Fusion's rating consensus is 'Buy'. The analyst rating breakdown for BMEA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biomea Fusion Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Joseph Pantginis | H.C. Wainwright | $15.00 | $4.24 | 253.78% | 91.08% |
| Jun 07, 2024 | George Farmer | Scotiabank | $21.00 | $11.27 | 86.34% | 167.52% |
| Jun 07, 2024 | Peter Lawson | Barclays | $5.00 | $11.27 | -55.63% | -36.31% |
| Jun 14, 2022 | Joseph Pantginis | H.C. Wainwright | $16.00 | $8.50 | 88.22% | 103.82% |
The latest Biomea Fusion stock forecast, released on Jun 07, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $15.00, which represents a 253.78% increase from the stock price at the time of the forecast ($4.24), and a 91.08% increase from BMEA last price ($7.85).
Biomea Fusion Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $13.67 |
| Last Closing Price | $7.85 | $7.85 | $7.85 |
| Upside/Downside | -100.00% | -100.00% | 74.14% |
In the current month, the average price target of Biomea Fusion stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biomea Fusion's last price of $7.85. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 26, 2024 | Rodman & Renshaw | - | Neutral | Initialise |
| Jun 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 07, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Jun 07, 2024 | Barclays | - | Equal-Weight | Downgrade |
| Jun 07, 2024 | Barclays | - | Hold | Downgrade |
| May 30, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Apr 07, 2023 | Citigroup | Buy | Buy | Hold |
Biomea Fusion's last stock rating was published by Rodman & Renshaw on Jun 26, 2024. The company Initialise its BMEA rating from "null" to "Neutral".
Biomea Fusion Financial Forecast
Biomea Fusion Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Biomea Fusion's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BMEA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Biomea Fusion EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict BMEA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biomea Fusion's previous annual EBITDA (undefined) of $NaN.
Biomea Fusion Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-28.82M | $-27.78M | $-25.67M | $-24.62M | $-30.75M | $-29.64M | $-27.39M | $-26.27M | $-30.82M | $-31.08M | $-30.43M | $-30.02M | $-31.54M | $-34.67M | $-38.81M |
| High Forecast | $-28.82M | $-27.78M | $-25.67M | $-24.62M | $-30.75M | $-29.64M | $-27.39M | $-26.27M | $-30.82M | $-31.08M | $-30.43M | $-30.02M | $-31.54M | $-33.68M | $-38.81M |
| Low Forecast | $-28.82M | $-27.78M | $-25.67M | $-24.62M | $-30.75M | $-29.64M | $-27.39M | $-26.27M | $-30.82M | $-31.08M | $-30.43M | $-30.02M | $-31.54M | $-35.66M | $-38.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Biomea Fusion's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BMEA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Biomea Fusion SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Biomea Fusion's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BMEA last annual SG&A of $NaN (undefined).
Biomea Fusion EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.80 | $-0.77 | $-0.71 | $-0.68 | $-0.85 | $-0.82 | $-0.76 | $-0.73 | $-0.85 | $-0.86 | $-0.84 | $-0.83 | $-0.88 | $-0.96 | $-1.08 |
| High Forecast | $-0.80 | $-0.77 | $-0.71 | $-0.68 | $-0.85 | $-0.82 | $-0.76 | $-0.73 | $-0.85 | $-0.86 | $-0.84 | $-0.83 | $-0.88 | $-0.93 | $-1.08 |
| Low Forecast | $-0.80 | $-0.77 | $-0.71 | $-0.68 | $-0.85 | $-0.82 | $-0.76 | $-0.73 | $-0.85 | $-0.86 | $-0.84 | $-0.83 | $-0.88 | $-0.99 | $-1.08 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Biomea Fusion's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BMEA previous annual EPS of $NaN (undefined).
Biomea Fusion Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
BMEA Forecast FAQ
Is Biomea Fusion a good buy?
Yes, according to 5 Wall Street analysts, Biomea Fusion (BMEA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of BMEA's total ratings.
What is BMEA's price target?
Biomea Fusion (BMEA) average price target is $13.67 with a range of $5 to $21, implying a 74.14% from its last price of $7.85. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Biomea Fusion stock go up soon?
According to Wall Street analysts' prediction for BMEA stock, the company can go up by 74.14% (from the last price of $7.85 to the average price target of $13.67), up by 167.52% based on the highest stock price target, and down by -36.31% based on the lowest stock price target.
Can Biomea Fusion stock reach $12?
BMEA's average twelve months analyst stock price target of $13.67 supports the claim that Biomea Fusion can reach $12 in the near future.
What are Biomea Fusion's analysts' financial forecasts?
Biomea Fusion's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-114M (high $-114M, low $-114M), average SG&A $0 (high $0, low $0), and average EPS is $-3.164 (high $-3.164, low $-3.164). BMEA's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-107M (high $-107M, low $-107M), average SG&A $0 (high $0, low $0), and average EPS is $-2.965 (high $-2.965, low $-2.965).